Anti-TIGIT antibody tiragolumab improves PD-L1 blockade via myeloid and Treg cells
Xiangnan Guan(Unknown), Pallavi Daggumati, Barzin Y. Nabet(Gene Therapy Laboratory), Shyam Srivats, Katherine Nutsch, Joy Han, Lisa McGinnis(Stanford Medicine), Alexis Dunkle(Duke University Hospital), Robert L. Hendricks(University of Pittsburgh), Nandini Molden, Patrick Chang, Stephanie Mittman(Translational Research in Oncology), Ellen Duong(IIT@MIT), Ruozhen Hu, Karl L. Banta(Cancer Research Institute), Yoonha Choi(Ewha Womans University), John Silva
Cited by 1
Related Papers
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
|Cell|2014|798
Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia
|Nature Biotechnology|2019|573